Related Experiment Video
Updated: May 15, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Osteoporosis in chronic liver disease
Anitha Yadav1, Elizabeth J Carey
1Division of Transplant Hepatology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
Summary
Osteoporosis is a frequent complication in chronic liver disease, affecting 11-58% of patients. Early diagnosis and management are crucial to prevent fractures and improve quality of life.
Area of Science:
- Hepatology
- Endocrinology
- Bone Metabolism
Background:
- Osteoporosis is a common skeletal complication in chronic liver disease (CLD).
- It often presents asymptomatically, leading to fractures and reduced quality of life if untreated.
- Prevalence ranges from 11% to 58% in CLD patients and transplant recipients.
Purpose of the Study:
- To review the prevalence, pathophysiology, diagnosis, and management of osteoporosis in CLD.
- To synthesize current knowledge on bone loss mechanisms in CLD.
- To highlight current and future therapeutic strategies.
Main Methods:
- Systematic literature search of the PubMed database.
- Inclusion of recent peer-reviewed articles on osteoporosis in CLD.
- Review of studies on prevalence, etiology, diagnosis, and management.
Main Results:
- Osteoporosis prevalence varies widely (11-58%) in CLD and transplant populations.
- Bone loss is multifactorial, involving vitamin D, calcium, IGF-1, RANKL, bilirubin, and genetic factors.
- Bone mineral density (BMD) assessment via DXA is recommended for advanced CLD and transplant patients.
Conclusions:
- Management includes early diagnosis, risk factor modification, nutrition, and pharmacotherapy.
- Bisphosphonates are primary treatments but carry risks like atypical fractures.
- Novel agents and improved fracture prevention strategies are needed.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...